Cancer Family
Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000045Explore in graph →
Non-malignant207 active trials6 approved drugs6 evidence items
- NCIt
- C7337
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000045Explore in graph →
Clinical trials
887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01478685 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 169 | CelgeneINDUSTRY | 4 | Nov 12, 2019 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00478452 | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients(DC-Ova) | completed | Phase 1 | 14 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00407407 | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | terminated | Phase 1 | 6 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01281514 | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | completed | Phase 1 | 21 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT00357448 | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | completed | Phase 1 | 11 | University of WashingtonOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT03283943 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | unknown | Phase 1 | 22 | British Columbia Cancer AgencyOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02534922 | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer(ProlantaOC) | unknown | Phase 1 | 18 | Oncolix, Inc.INDUSTRY | 1 | Feb 14, 2018 | clinicaltrials |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00287859 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 1 | 5 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00625092 | Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01898715 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | completed | Phase 1 | 63 | Millendo Therapeutics, Inc.INDUSTRY | 2 | Nov 6, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01416038 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 19 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Apr 21, 2017 | clinicaltrials |
| NCT01248273 | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01308944 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | terminated | Phase 1 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01384253 | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | completed | Phase 1 | 18 | Orano Med LLCINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 17, 2016 | clinicaltrials |
| NCT00066456 | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 13 | Gynecologic Oncology GroupNETWORK | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00702299 | Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | completed | Phase 1 | 15 | University of ArizonaOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00591643 | Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59) | completed | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT01832974 | Possible New Therapy for Advanced Cancer | terminated | Phase 1 | 9 | INSYS Therapeutics IncINDUSTRY | 1 | Apr 27, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2019source: clinicaltrials